EUVIMEDEUVIMED entdecken
Crossref

Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design

Johannes Krieger, Fiona J Sorrell iD, Ansgar A Wegener, Birgitta Leuthner, Fouzia Machrouhi-Porcher, Martin Hecht, Eva M Leibrock, Juliane E Müller, Jonathan Eisert, Ingo V Hartung iD, Sarah Schlesiger iD

ChemMedChem · 17.04.2023 · 18 (8)

DOI: 10.1002/cmdc.202200615 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 28.02.2023. Verfasst von Johannes Krieger und 10 weiteren Autor:innen. Beteiligte Einrichtung: Discovery and Development Technologies, Merck Healthcare KGaA, Frankfurter Straße 250, 64293, Darmstadt, Germany. Hauptthemen laut MEDLINE: Von Hippel-Lindau Tumor Suppressor Protein, Nuclear Proteins. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 62 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Herein, we describe a systematic SAR‐ and SPR‐investigation of the peptidomimetic hydroxy‐proline based VHL‐ligand VH032, from which most to‐date published VHL‐targeting PROTACs have been derived. This study provides for the first time a consistent data set which allows for direct comparison of structural variations including those which were so far hidden in patent literature. The gained knowledge about improved VHL binders was used to design a small library of highly potent BRD4‐degraders comprising different VHL exit vectors. Newly designed degraders showed favorable molecular properties and significantly improved degradation potency compared to MZ1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Von Hippel-Lindau Tumor Suppressor ProteinNuclear ProteinsLigandsProteolysisTranscription FactorsUbiquitin-Protein Ligases

Stichwörter der Autor:innen

PROTACVon Hippel Lindauligand designprotein degradationstructure-activity relationships

Substanzen

Von Hippel-Lindau Tumor Suppressor ProteinLigandsNuclear ProteinsTranscription FactorsUbiquitin-Protein Ligases

Autor:innen und Institutionen

  • Discovery and Development Technologies, Merck Healthcare KGaA, Frankfurter Straße 250, 64293, Darmstadt, Germany.
  • Site Management Analytics, Merck KGaA, Frankfurter Straße 250, 64293, Darmstadt, Germany.

ORCID-Profile: Fiona J Sorrell, Ingo V Hartung, Sarah Schlesiger

Zitieren

APA

Krieger, J., Sorrell, F. J., Wegener, A. A., Leuthner, B., Machrouhi-Porcher, F., Hecht, M., Leibrock, E. M., Müller, J. E., Eisert, J., Hartung, I. V., & Schlesiger, S. (2023). Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design. ChemMedChem, 18(8). https://doi.org/10.1002/cmdc.202200615

Vancouver

Krieger J, Sorrell FJ, Wegener AA, Leuthner B, Machrouhi-Porcher F, Hecht M, et al. Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design. ChemMedChem. 2023;18(8). doi:10.1002/cmdc.202200615

BibTeX
@article{Krieger2023,
  author = {Krieger, Johannes and Sorrell, Fiona J and Wegener, Ansgar A and Leuthner, Birgitta and Machrouhi-Porcher, Fouzia and Hecht, Martin and Leibrock, Eva M and Müller, Juliane E and Eisert, Jonathan and Hartung, Ingo V and Schlesiger, Sarah},
  title = {Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design},
  journal = {ChemMedChem},
  year = {2023},
  volume = {18},
  number = {8},
  doi = {10.1002/cmdc.202200615}
}
Kostenlos starten →